Pfizer (PFE): Declines in COVID-19 products expected to drag down overall revenue in 2023
usx:pfe Blog PostFundamental Research Corp. initiates coverage of Ocean Biomedical (OCEA) with “Buy” recommendation
usx:pfe usx:ocea Blog PostPfizer (PFE) expects COVID franchise to reach low point in 2023 and then rebound in 2024
usx:pfe Blog PostPfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day
usx:pfe Blog PostPfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
usx:pfe Blog PostThe Law Offices of Frank R. Cruz Announces Investigation of Pfizer Inc. (PFE) on Behalf of Investors
usx:pfe Blog PostPfizer (PFE): A look at the headwinds and tailwinds this pharma giant faces in the near term
usx:pfe Blog Post